In short
Clear cell papillary renal cell tumor is a rare form of kidney cancer that typically grows slowly and has a more favorable outlook than many other kidney cancers. Understanding how this condition is treated, from well-established surgical approaches to experimental therapies currently being tested in clinical trials, can help patients and families make informed decisions alongside their medical teams.
Key points
- Clear cell papillary renal cell tumor is a rare and relatively benign form of kidney cancer that accounts for only 1 to 4 percent of all kidney cancers.
- Surgery, particularly partial nephrectomy, is the main treatment and is often curative, with no recurrence reported in most follow-up studies.
- CCPRCT is frequently discovered by accident during imaging tests for other health issues, often when the tumor is still small and easy to remove.
- The tumor's unique appearance under a microscope, with clear bubble-like cells and rows of nuclei, helps doctors distinguish it from more aggressive kidney cancers.
- Targeted therapies and immunotherapy are being studied for advanced kidney cancers and may be options for CCPRCT if the tumor spreads, though this is rare.
- The World Health Organization now classifies CCPRCT as a tumor rather than a carcinoma due to its less aggressive behavior and low risk of spreading.
- Preserving kidney function is a priority in treatment, which is why partial nephrectomy is preferred whenever the tumor's size and location allow it.
- Clinical trials exploring combination therapies and new drugs for kidney cancer may offer future treatment options, even for rare subtypes like CCPRCT.
Managing a Rare Kidney Tumor: What Treatment Aims to Achieve
When someone receives a diagnosis of clear cell papillary renal cell tumor, often shortened to CCPRCT, the primary goal of treatment is to remove or control the tumor while preserving as much kidney function as possible. This particular type of kidney cancer is now classified by the World Health Organization as a tumor rather than a full carcinoma due to its relatively benign nature, meaning it tends to behave less aggressively than other kidney cancers. The tumor usually grows slowly and is less likely to spread to other parts of the body compared to more aggressive kidney cancer subtypes.
Treatment decisions depend heavily on the tumor's size, location, and whether it has been detected early. Many cases of CCPRCT are discovered accidentally during imaging tests ordered for unrelated health concerns, which often means the tumor is caught at an early, manageable stage. Because CCPRCT accounts for only about 1 to 4 percent of all kidney cancers, it remains relatively uncommon, and each patient's treatment plan must be tailored to their specific circumstances.
Modern treatment approaches aim not only to eliminate the cancer but also to maintain quality of life. For patients with small tumors and no signs of spread, doctors may focus on removing just the tumor itself, sparing the rest of the kidney. This is particularly important because the kidneys play a vital role in filtering waste from the blood, and preserving kidney function helps patients avoid complications such as the need for dialysis later in life.
There are established, guideline-recommended treatments that have been used successfully for years, and there are also new therapies being explored in clinical trials. These research studies test innovative approaches that might one day become standard treatment options, offering hope for even better outcomes in the future.
Standard Treatment Approaches for Clear Cell Papillary Renal Cell Tumor
The cornerstone of treatment for CCPRCT is surgery. Because this tumor type tends to be discovered when it is small and has not spread, surgical removal is often curative. The two main surgical options are partial nephrectomy, where only the tumor and a small margin of surrounding tissue are removed, and radical nephrectomy, where the entire kidney is taken out. The choice between these procedures depends on the tumor's size, location, and the patient's overall kidney function.
Partial nephrectomy is the preferred approach whenever possible, especially for patients with small tumors. In a study of 36 patients with CCPRCT, 29 underwent partial nephrectomy with good results. The median tumor size in these cases was just 1.2 centimeters, which is quite small. The surgery typically took around 97 minutes, with an estimated blood loss of about 100 milliliters, which is relatively minimal. Most patients stayed in the hospital for about four days, and serious complications were rare.
For patients with end-stage renal disease, a condition where the kidneys have already lost most of their function and the patient requires dialysis, radical nephrectomy may be necessary. In the same study, seven patients with end-stage renal disease underwent this more extensive surgery. CCPRCT was first recognized in patients with end-stage renal disease, though it is now known to occur in people with healthy kidneys as well.
The positive news is that CCPRCT has an excellent prognosis following surgery. In the study mentioned above, with a median follow-up period of nearly 27 months, there were no cases of cancer recurrence and no deaths related to the cancer. This suggests that surgical removal of the tumor is highly effective for this type of kidney cancer.
In addition to removing the tumor surgically, doctors may also use imaging tests such as CT scans, MRI scans, and ultrasounds to monitor the tumor before and after surgery. These tests help determine the size and exact location of the tumor, and they are also used to check whether the cancer has spread to other parts of the body. Imaging is a crucial part of both diagnosis and follow-up care, ensuring that any changes are detected early.
Currently, there are no standard medications or systemic therapies specifically approved for CCPRCT in the way there are for more aggressive forms of kidney cancer like clear cell renal cell carcinoma. This is largely because CCPRCT is so rarely aggressive and surgical removal is usually sufficient. However, if the tumor were to spread, doctors might consider treatments used for other types of kidney cancer, such as targeted therapies or immunotherapy, though this is not commonly needed for CCPRCT.
Experimental and Emerging Treatments in Clinical Trials
Because CCPRCT is rare and typically has such a good prognosis with surgery alone, there are not many clinical trials specifically focused on this tumor subtype. However, researchers studying kidney cancer more broadly are investigating new therapies that could benefit patients with various types of renal tumors, including CCPRCT, especially in the rare cases where the tumor grows more aggressively or spreads.
One area of active research involves targeted therapies, which are drugs designed to attack specific molecules or pathways that cancer cells use to grow and survive. For example, many kidney cancers, including some that share features with CCPRCT, are driven by problems with the VHL gene, which leads to the overproduction of vascular endothelial growth factor (VEGF). VEGF is a protein that helps tumors grow new blood vessels to supply them with nutrients. Drugs that block VEGF or its receptors, such as cabozantinib, axitinib, sunitinib, sorafenib, and pazopanib, have been approved for treating clear cell renal cell carcinoma and are sometimes used for other kidney cancer subtypes in clinical trial settings.
These targeted therapies work by interfering with the cancer cells' ability to create blood vessels, effectively starving the tumor of the resources it needs to grow. They are typically taken as oral pills and can be continued for months or even years, depending on how well they work and what side effects occur. Common side effects of these medications include fatigue, high blood pressure, diarrhea, and skin changes. Patients taking targeted therapies require regular monitoring by their medical team to manage these effects and adjust treatment as needed.
Immunotherapy is another promising area of research. These treatments help the body's own immune system recognize and attack cancer cells. Drugs known as immune checkpoint inhibitors, which include medications like nivolumab and pembrolizumab, have shown success in treating clear cell renal cell carcinoma and are being studied in other kidney cancer types. Immunotherapy works by blocking proteins that prevent immune cells from attacking cancer, essentially taking the brakes off the immune system. While there is no specific data yet on immunotherapy for CCPRCT, these drugs are sometimes considered for patients with advanced kidney cancer that has not responded to surgery or other treatments.
Clinical trials for kidney cancer often enroll patients with various subtypes, including rare forms like CCPRCT, particularly when standard treatment options have been exhausted. These trials may be conducted at major cancer centers in the United States, Europe, and other regions around the world. Patients interested in participating in a clinical trial should discuss this option with their oncologist, who can help determine if there is an appropriate trial available and if the patient meets the eligibility criteria.
In some clinical trials, researchers are exploring combination therapies that pair targeted drugs with immunotherapy. The idea is that by attacking the cancer in multiple ways at once, the treatment may be more effective. For example, combining a VEGF inhibitor with an immune checkpoint inhibitor has shown promise in treating more aggressive kidney cancers. While this approach has not been specifically tested for CCPRCT, it represents an important direction in kidney cancer research.
Trials typically progress through three phases. Phase I trials focus on safety, determining the correct dose of a new drug and identifying side effects. Phase II trials test whether the drug is effective at shrinking tumors or slowing cancer growth. Phase III trials compare the new treatment to the current standard of care to see if it offers an improvement. Patients who enroll in these studies contribute valuable information that helps advance medical knowledge and may benefit from access to cutting-edge therapies before they become widely available.
Most common treatment methods
- Surgery
- Partial nephrectomy: removal of the tumor and a small margin of surrounding kidney tissue, preserving most of the kidney
- Radical nephrectomy: removal of the entire affected kidney, typically used when the tumor is large or the kidney is not functioning
- Median operative time for partial nephrectomy is approximately 97 minutes with minimal blood loss
- Hospital stays typically last around four days following surgery
- No recurrence or cancer-related deaths reported in follow-up studies of CCPRCT patients after surgery
- Targeted therapy (experimental or for advanced cases)
- Cabozantinib, axitinib, sunitinib, sorafenib, and pazopanib: drugs that block vascular endothelial growth factor (VEGF) to prevent tumor blood vessel growth
- Typically used in clear cell renal cell carcinoma and may be considered for CCPRCT if the tumor spreads
- Administered as oral medications
- Common side effects include fatigue, high blood pressure, diarrhea, and skin changes
- Immunotherapy (experimental or for advanced cases)
- Immune checkpoint inhibitors such as nivolumab and pembrolizumab help the immune system attack cancer cells
- Used primarily in clear cell renal cell carcinoma and being studied in other kidney cancer subtypes
- May be considered for CCPRCT that does not respond to surgery or other treatments
- Imaging and monitoring
- CT scans, MRI scans, and ultrasounds used to assess tumor size and location before surgery
- Follow-up imaging to check for recurrence or spread after treatment
- Particularly important for detecting tumors early, as many CCPRCT cases are found incidentally
